Please login to the form below

Not currently logged in
Email:
Password:

Amgen veteran Kurt Gustafson joins Spectrum as CFO

Biotech also creates new senior financial position for Brett Scott

Spectrum Kurt GustafsonSpectrum Pharmaceuticals has appointed Kurt Gustafson as its executive VP, chief financial officer and principal accounting officer.

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.

Prior to this role, he spent more than 18 years at Amgen, holding such positions as chief financial office of Amgen International and VP finance.

In addition to Gustafson's appointment, Spectrum also announced that the company's senior VP and acting chief financial officer Brett Scott has been appointed to the newly-created role of senior VP of finance.

Dr Rajesh Shrotriya, chairman, CEO and president of Spectrum, explained why the company had created the new role and appointed Gustafson.

"We believe this is a time of rapid growth at Spectrum, and the business is becoming more complex,” he said.

“Kurt brings in over 20 years of experience in finance and is a key addition to our already strong management team. We look forward to working with Kurt as we continue to build our business and execute our goals."

7th June 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics